New study checks safety of triple therapy inhaler for COPD patients
NCT ID NCT06531798
First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study is monitoring the safety and tolerability of Breztri Aerosphere, a triple-combination inhaler, in 150 Indian patients with moderate to severe COPD. Participants will use the inhaler as maintenance treatment while researchers track side effects. The goal is to ensure the drug is safe for long-term use in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Breztri Aerosphere (budesonide, glycopyrronium, formoterol)
- What this could lead to
- If successful, this study will confirm that Breztri Aerosphere is safe and well-tolerated for long-term use in managing moderate to severe COPD.
- What could go wrong
- This is an observational safety study, not designed to prove new benefits. Side effects like pneumonia or allergic reactions are possible, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGDalgate, Drugjan, 190001, India
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
NOT_YET_RECRUITINGLucknow, 226010, India
-
Research Site
RECRUITINGNagpur, 440010, India
-
Research Site
RECRUITINGNew Delhi, 110029, India